Departments of Clinical Microbiology, IIS-Fundación Jiménez Díaz, UAM , Madrid, Spain.
Internal Medicine-Sepsis Unit, IIS-Fundación Jiménez Díaz, UAM , Madrid, Spain.
Expert Opin Pharmacother. 2020 Jun;21(8):969-981. doi: 10.1080/14656566.2020.1740205. Epub 2020 Mar 21.
Non-tuberculous Mycobacteria (NTM) are a group of organisms whose importance in medicine seems to be increasing in recent times. The increasing number of patients susceptible to these diseases make it necessary to expand our knowledge of therapeutic options and to explore future possibilities for the development of a therapeutic arsenal.
In this review, the authors provide a brief introduction about the present importance of NTM and describe the present recommendations of the available guidelines for their treatment. They include a description of the future options for the management of these patients, especially focusing on new antibiotics. The authors also look at possibilities for future therapeutic options, such as antibiofilm strategies.
No actual changes have been made to the current recommendations for the management of most NTM infections (except perhaps the availability of nebulized amikacin). However, it is also true that we have increased the number of available antibiotic treatment options with good in vitro activity against NTM. The use of these drugs in selected cases could increase the therapeutic possibilities. However, some problems are still present, such as the knowledge of the actual meaning of a NTM isolate, and will probably be a key part of future research.
非结核分枝杆菌(NTM)是一组生物体,其在医学中的重要性似乎在最近有所增加。越来越多的患者易患这些疾病,这使得我们有必要扩大对治疗选择的了解,并探索未来开发治疗武器库的可能性。
在这篇综述中,作者简要介绍了 NTM 的当前重要性,并描述了目前针对这些疾病治疗的可用指南的建议。他们包括对这些患者管理的未来选择的描述,特别是对新型抗生素的关注。作者还研究了未来治疗选择的可能性,例如抗生物膜策略。
目前对大多数 NTM 感染的管理建议实际上并没有改变(除了雾化阿米卡星的可用性可能有所增加)。然而,我们确实增加了对 NTM 具有良好体外活性的可用抗生素治疗选择的数量。在选定的情况下使用这些药物可以增加治疗的可能性。然而,仍然存在一些问题,例如对 NTM 分离株实际意义的了解,这可能是未来研究的关键部分。